PHSSR Saudi Arabia 2025

Authors Hisham A. Badreldin King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs Ahmad Al-jedai Therapeutic Affairs, Ministry of Health; Colleges of Pharmacy and Medicine, Alfaisal University Suliman Alghnam King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs Ziad Nakshabandi National Center for Health Workforce Planning, Saudi Commission for Health Specialties Muaddi Alharbi The Studies and Consulting O ffice at the Assistant Minister of Health Abdulaziz Alzahrani National Center for Health Workforce Planning, Saudi Commission for Health Specialties Hanan Alqadri King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs Hajer Almodeiheem Therapeutic Affairs, Ministry of Health Raed Alhazmi King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs Azah Althumairi King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs , Fahmi Al-Senani Model of Care – Center of Excellence, Ministry of Health Sarah Althari Saudi Ministry of Investment Bandar AlKnawy King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center; King Abdulaziz Medical City, National Guard Health Affairs This report was produced as part of the Partnership for Health System Sustainability and Resilience (PHSSR). The PHSSR is a collaboration between AstraZeneca, the London School of Economics and Political Science (LSE), Royal Philips, the World Economic Forum, the Center for Asia-Paci fic Resilience & Innovation (CAPRI), IQVIA and the WHO Foundation, motivated by a shared commitment to strengthen health systems and improve population health. AstraZeneca and Royal Philips fund the partnership. This report was written on behalf of the PHSSR. The positions and arguments presented are the authors’ own. They do not represent the views of the PHSSR partners listed above. This report was prepared during 2022 –2023. While the information presented was accurate at the time of writing, some data, statistics, and findings may no longer re flect current conditions. Readers should verify time-sensitive information and consider seeking updated sources where relevant. For further information on the PHSSR, including additional country reports, please visit www.phssr.org This report was commissioned via LSE Consulting which was set up by The London School of Economics and Political Science to enable and facilitate the application of its academic expertise and intellectual resources. LSE Enterprise Ltd, trading as LSE Consulting, is a wholly owned subsidiary of the London School of Economics and Political Science. The LSE trademark is used under licence from the London School of Economics and Political Science. LSE Consulting LSE Enterprise Ltd London School of Economics and Political Science Houghton Street, London, WC2A 2AE (T) +44 (0)20 7106 1198 (E) [email protected] (W) lse.ac.uk/consultancy